Coeptis therapeutics engages iqvia to support snap-car development program

Coeptis to collaborate with iqvia, a global contract research organization, to identify target indications and initiate ind-enabling activities for snap-car wexford, pa. , nov. 22, 2022 /prnewswire/ -- coeptis therapeutics holdings, inc. (nasdaq: coep)  ("coeptis" or "the company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced an agreement with iqvia, a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, to support the development of snap-car, a multi-antigen chimeric antigen receptor t cell (car t) technology that coeptis licensed from the university of pittsburgh.
IQV Ratings Summary
IQV Quant Ranking